Prevention Ventilator Associated Pneumonia
Not Applicable
Completed
- Conditions
- Ventilator-associated Pneumonia
- Interventions
- Other: Bundle implementation
- Registration Number
- NCT02060045
- Lead Sponsor
- Maria Jesus Perez
- Brief Summary
The objective of the investigators work was to evaluate the impact of 4 sequentially implemented measures for preventing VAP in a major heart surgery ICU. The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1534
Inclusion Criteria
- all patients with heart surgery admitted in critical care unit during the study period
Exclusion Criteria
- none
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description bundle implementation Bundle implementation The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
- Primary Outcome Measures
Name Time Method Change (reduction) in the incidence density of Ventilator associated pneumonia (VAP) Baseline and up to 35 months Change (reduction) in the incidence density of VAP
- Secondary Outcome Measures
Name Time Method Change(length) in Intensive Care Unit (ICU) stay Baseline and up to 35 months Change (number of days) in Mechanical Ventilator (MV) per ICU stay Baseline and up to 35 months Change in mortality rate Baseline and up to 35 months Change in cost of antimicrobial acquisition during ICU stay Baseline and up to 35 months Change in compliance with the measures Baseline and up to 35 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie chlorhexidine's efficacy in disrupting oral biofilms to prevent VAP in cardiac ICU patients?
How does sequential implementation of subglottic secretion aspiration and inclinometer-guided positioning compare to standard VAP prevention protocols in post-cardiac surgery ICUs?
Which biomarkers predict response to multimodal VAP prevention strategies involving chlorhexidine and semirecumbent positioning in high-risk surgical patients?
What are the potential adverse events associated with prolonged semirecumbent positioning in heart surgery ICU patients using inclinometers?
What combination therapies synergize with chlorhexidine-based oral care to enhance VAP prevention in mechanically ventilated cardiac surgery patients?
Trial Locations
- Locations (1)
Hopsital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain